← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

DBVT logoDBV Technologies S.A.(DBVT)Earnings, Financials & Key Ratios

DBVT•NASDAQ
$19.49
$1669.52T mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryImmunology and Inflammation Therapies
AboutDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Show more
  • Revenue$0
  • EBITDA-$135M-19.2%
  • Net Income-$147M-29.6%
  • EPS (Diluted)-26.40-347.5%
  • ROE-150.29%-10.7%
  • Debt/Equity0.13-54.9%
Analysis→Technical→

DBVT Key Insights

DBV Technologies S.A. (DBVT) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 80 (top 20%)
  • ✓Share count reduced 71.0% through buybacks
  • ✓Trading at only 0.6x book value

✗Weaknesses

  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

DBVT Price & Volume

DBV Technologies S.A. (DBVT) stock price & volume — 10-year historical chart

Loading chart...

DBVT Growth Metrics

DBV Technologies S.A. (DBVT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-100%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-47.7%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM11.82%

Return on Capital

10 Years-80.79%
5 Years-87.77%
3 Years-107.22%
Last Year-145.72%

DBVT Recent Earnings

DBV Technologies S.A. (DBVT) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 30, 2026
EPS
$0.13
Est $0.13
+0.9%
Revenue
$1M
Est $1M
-4.9%
Q2 2026
Mar 27, 2026
EPS
$1.15
Est $1.30
+11.5%
Revenue
$574,600
Est $1M
-60.5%
Q2 2026
Mar 26, 2026
EPS
$1.15
Est $1.30
+11.5%
Revenue
$574,600
Est $1M
-60.5%
Q4 2025
Oct 28, 2025
EPS
$1.20
Est $1.45
+17.2%
Revenue
$3M
Est $1M
+204.5%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 30, 2026
$0.13vs $0.13+0.9%
$1Mvs $1M-4.9%
Q2 2026Mar 27, 2026
$1.15vs $1.30+11.5%
$574,600vs $1M-60.5%
Q2 2026Mar 26, 2026
$1.15vs $1.30+11.5%
$574,600vs $1M-60.5%
Q4 2025Oct 28, 2025
$1.20vs $1.45+17.2%
$3Mvs $1M+204.5%
Based on last 12 quarters of dataView full earnings history →

DBVT Peer Comparison

DBV Technologies S.A. (DBVT) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
ALKS logoALKSAlkermes plcDirect Competitor6.12B36.2525.35-5.25%16.37%14.45%7.85%0.04
PRGO logoPRGOPerrigo Company plcDirect Competitor1.6B11.64-1.13-2.75%-33.51%-48.56%9.06%0.01
SLRX logoSLRXSalarius Pharmaceuticals, Inc.Direct Competitor697.79K0.74-0.01-117.81%0.15
SNGX logoSNGXSoligenix, Inc.Direct Competitor3.21M0.32-0.06-267.1%0.36
HALO logoHALOHalozyme Therapeutics, Inc.Direct Competitor7.76B65.8725.7337.55%22.69%6.49%8.31%
ALK logoALKAlaska Air Group, Inc.Product Competitor4.41B38.5144.2621.34%0.7%2.43%1.67
REGN logoREGNRegeneron Pharmaceuticals, Inc.Product Competitor72.97B702.3316.930.99%29.65%14.32%5.59%0.09
SANA logoSANASana Biotechnology, Inc.Product Competitor915.3M3.49-3.01-120.02%0.38

Compare DBVT vs Peers

DBV Technologies S.A. (DBVT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ALKS

Most directly comparable listed peer for DBVT.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare DBVT against a more recognizable public peer.

Peer Set

Compare Top 5

vs ALKS, PRGO, SLRX, SNGX

DBVT Income Statement

DBV Technologies S.A. (DBVT) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue11.52M12.81M14.71M11.28M5.71M4.8M15.73M000
Revenue Growth %45.31%11.25%14.77%-23.33%-49.38%-15.91%227.67%-100%--100%
Cost of Goods Sold3.43M5.03M009.27M20.3M06.81M17.67M13.18M
COGS % of Revenue29.8%39.27%--162.46%422.9%----
Gross Profit
11.52M▲ 0%
12.81M▲ 11.3%
14.71M▲ 14.8%
11.28M▼ 23.3%
-3.56M▼ 131.6%
-15.5M▼ 334.8%
15.73M▲ 201.5%
-6.81M▼ 143.3%
-17.67M▼ 159.4%
-13.18M▲ 0%
Gross Margin %100%100%100%100%-62.46%-322.9%100%---
Gross Profit Growth %45.31%11.25%14.77%-23.33%-131.62%-334.75%201.48%-143.32%-159.39%-
Operating Expenses185.46M203.22M192.8M170.12M93.93M101.47M92.16M113.71M135.49M151.58M
OpEx % of Revenue1610.07%1585.77%1310.86%1508.67%1645.6%2114.06%585.96%---
Selling, General & Admin61.47M82.19M70.73M44.96M23.83M17.56M31.94M23.81M28.37M30.49M
SG&A % of Revenue533.65%641.33%480.89%398.72%417.43%365.9%203.06%---
Research & Development126.25M123.5M112.24M101.61M70.34M75.5M60.22M89.9M107.12M121.86M
R&D % of Revenue1096.04%963.68%763.13%901.09%1232.24%1572.92%382.9%---
Other Operating Expenses-5.21M-6.96M9.83M23.55M-232K8.41M-1K01-763.21K
Operating Income
-173.94M▲ 0%
-190.12M▼ 9.3%
-171.02M▲ 10.0%
-158.84M▲ 7.1%
-98.61M▲ 37.9%
-96.63M▲ 2.0%
-76.43M▲ 20.9%
-120.53M▼ 57.7%
-153.16M▼ 27.1%
-124.76M▲ 0%
Operating Margin %-1509.99%-1483.57%-1162.79%-1408.67%-1727.65%-2013.15%-485.96%---
Operating Income Growth %-42.42%-9.3%10.04%7.12%37.92%2.01%20.9%-57.69%-27.08%-
EBITDA-170.64M-186.88M-168.43M-148.38M-90.24M-76.33M-63.27M-113.71M-135.49M-111.58M
EBITDA Margin %-1481.34%-1458.31%-1145.15%-1315.9%-1580.9%-1590.25%-402.28%---
EBITDA Growth %-41.45%-9.52%9.87%11.9%39.18%15.41%17.11%-79.73%-19.15%-3.58%
D&A (Non-Cash Add-back)3.3M3.24M2.6M10.46M8.38M20.3M13.16M6.81M17.67M13.18M
EBIT-173.36M-190.43M-171.02M-135.29M-99.53M-96.98M-76.43M-117.8M-153.16M-124.55M
Net Interest Income-3.25M162.44K-377.93K-724K-169K-20.71K3.71M2.73M601.86K1.05M
Interest Income867.09K563.94K00521K406.29K3.71M2.73M601.86K1.7M
Interest Expense3.99M479.76K377.93K724K690K427K000656.16K
Other Income/Expense-3.25M161.53K-378K-723K424K427K3.71M2.73M601.86K-47.45M
Pretax Income
-177.11M▲ 0%
-190.24M▼ 7.4%
-171.4M▲ 9.9%
159.56M▲ 193.1%
-98.19M▼ 161.5%
-96.2M▲ 2.0%
-72.72M▲ 24.4%
-117.8M▼ 62.0%
-152.56M▼ 29.5%
-172.21M▲ 0%
Pretax Margin %-1537.56%-1484.52%-1165.35%1415.09%-1720.22%-2004.25%-462.35%---
Income Tax1.2K17.16K610K10K-381K70K7K-4.08M-5.16M-4.4M
Effective Tax Rate %-0%-0.01%-0.36%0.01%0.39%-0.07%-0.01%3.47%3.38%2.55%
Net Income
-177.2M▲ 0%
-190.26M▼ 7.4%
-172.01M▲ 9.6%
-159.56M▲ 7.2%
-97.81M▲ 38.7%
-96.3M▲ 1.5%
-72.73M▲ 24.5%
-113.72M▼ 56.4%
-147.4M▼ 29.6%
-167.81M▲ 0%
Net Margin %-1538.29%-1484.65%-1169.51%-1415%-1713.54%-2006.25%-462.4%---
Net Income Growth %-40.25%-7.37%9.59%7.24%38.7%1.54%24.48%-56.36%-29.62%-47.7%
Net Income (Continuing)-177.2M-190.26M-172.01M-159.56M-98.05M-96.27M-72.73M-113.72M-147.4M-167.81M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)
-42.00▲ 0%
-39.25▲ 6.5%
-26.40▲ 32.7%
-14.75▲ 44.1%
-8.90▲ 39.7%
-6.20▲ 30.3%
-3.80▲ 38.7%
-5.90▼ 55.3%
-26.40▼ 347.5%
0.00▲ 0%
EPS Growth %-757.14%6.55%32.74%44.13%39.66%30.34%38.71%-55.26%-347.46%11.82%
EPS (Basic)-42.00-39.25-26.40-14.75-8.90-6.20-3.80-5.90-26.40-
Diluted Shares Outstanding4.95M5.79M7.4M10.82M11.02M15.48M19.02M19.23M5.58M85.66T
Basic Shares Outstanding4.95M5.79M7.4M10.82M11.02M15.48M19.02M19.23M5.58M85.66T
Dividend Payout Ratio----------

DBVT Balance Sheet

DBV Technologies S.A. (DBVT) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets220.81M198.83M204.55M207.37M114.52M223.07M158.91M44.39M212.94M246.7M
Cash & Short-Term Investments194.08M167.81M193.25M196.35M77.3M209.19M141.37M32.46M194.17M229.2M
Cash Only194.08M167.81M193.25M196.35M77.3M209.19M141.37M32.46M194.17M229.2M
Short-Term Investments0000000000
Accounts Receivable19.87M20.15M5.41M7.86M33.07M10.49M15.45M10.39M16.15M0
Days Sales Outstanding629.47574.04134.23254.432.11K798358.43---
Inventory2.89M2.14M2.29M002.68M0000
Days Inventory Outstanding307.4155.23---48.19----
Other Current Assets20.79M25.25M0001K00017.5M
Total Non-Current Assets29.48M35.92M67.17M64.87M31.81M23.44M24.07M21.27M20.77M19.7M
Property, Plant & Equipment25.07M27.64M48.6M34.9M24.92M17.61M17.93M16.81M14.95M14.1M
Fixed Asset Turnover0.46x0.46x0.30x0.32x0.23x0.27x0.88x--0.00x
Goodwill000006610000
Intangible Assets173.14K41.01K48K41K22K9.34K58K40K22K100K
Long-Term Investments1.88M590.48K5.12M4.58M3.97M1.66M3.68M4.31M620K620K
Other Non-Current Assets1.55M5.78M13.41M25.35M2.9M5.83M2.4M111K5.19M21.48M
Total Assets
250.28M▲ 0%
234.76M▼ 6.2%
271.73M▲ 15.7%
272.25M▲ 0.2%
146.32M▼ 46.3%
246.52M▲ 68.5%
182.99M▼ 25.8%
65.66M▼ 64.1%
233.72M▲ 256.0%
266.4M▲ 0%
Asset Turnover0.05x0.05x0.05x0.04x0.04x0.02x0.09x--0.00x
Asset Growth %-21.09%-6.2%15.75%0.19%-46.25%68.48%-25.77%-64.12%255.96%727.19%
Total Current Liabilities50.58M59.52M54M52.71M31.4M29.52M37.34M31.14M58.02M51.8M
Accounts Payable23.85M39.05M24M20.34M11.43M14.47M23.3M22.03M40.94M0
Days Payables Outstanding2.54K2.83K--449.9260.24-1.18K845.48841.45
Short-Term Debt3.89M3.49M4.33M4.43M3.51M1.13M883K846K16.27M0
Deferred Revenue (Current)3.93M5.96M3.6M4.69M4.15M2.14M0000
Other Current Liabilities18.31M2.92M21.63M22.68M12.13M9.82M11.79M7.42M217K51.8M
Current Ratio4.37x3.34x3.79x3.93x3.65x7.56x4.26x1.43x3.67x3.67x
Quick Ratio4.31x3.30x3.75x3.93x3.65x7.47x4.26x1.43x3.67x3.67x
Cash Conversion Cycle-1.6K-2.1K---585.95----
Total Non-Current Liabilities16.83M9.46M24.54M14.04M15.9M22.54M5.46M7.13M6.92M6.7M
Long-Term Debt2.57M1.75M810K543K000000
Capital Lease Obligations0022M10.5M7.15M1.13M4.53M6.3M5.41M18.8M
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities14.26M7.71M1.74M3M8.75M21.42M934K838K1.51M10.76M
Total Liabilities67.4M68.98M78.54M66.75M47.29M52.06M42.8M38.27M64.95M58.4M
Total Debt6.46M5.24M27.14M15.47M10.66M4.15M6.55M7.8M21.68M0
Net Debt-187.62M-162.57M-166.12M-180.88M-66.64M-205.04M-134.81M-24.66M-172.48M-229.2M
Debt / Equity0.04x0.03x0.14x0.08x0.11x0.02x0.05x0.28x0.13x0.13x
Debt / EBITDA----------0.00x
Net Debt / EBITDA---------2.05x
Interest Coverage-43.46x-396.92x-452.53x-186.87x-144.25x-227.12x----189.82x
Total Equity
182.88M▲ 0%
165.78M▼ 9.4%
193.19M▲ 16.5%
205.49M▲ 6.4%
99.03M▼ 51.8%
194.45M▲ 96.4%
140.19M▼ 27.9%
27.39M▼ 80.5%
168.77M▲ 516.2%
207.9M▲ 0%
Equity Growth %-31.74%-9.35%16.53%6.37%-51.81%96.36%-27.91%-80.46%516.22%7659.39%
Book Value per Share36.9428.6626.1018.998.9912.567.371.4230.230.00
Total Shareholders' Equity182.88M165.78M193.19M205.49M99.03M194.45M140.19M27.39M168.77M207.9M
Common Stock3.52M4.12M5.64M6.52M6.54M10.72M10.97M11.65M26.08M33M
Retained Earnings-207.9M-227M-798.99M-958.54M-98.05M-259.58M-238.86M-286.38M-393.13M-440.7M
Treasury Stock00-230K-1.17M0-1.11M-1.26M-1.31M00
Accumulated OCI-185.23M-348.47M-643.87M6.64M-15.39M-13.8M-8.13M-12.19M-5.43M400K
Minority Interest0000000000

DBVT Cash Flow Statement

DBV Technologies S.A. (DBVT) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations-160.91M-186.74M-148.35M-165.61M-108.24M-55.7M-79.65M-104.47M-121.18M-121.18M
Operating CF Margin %-1396.92%-1457.2%-1008.61%-1468.67%-1896.32%-1160.42%-506.44%---
Operating CF Growth %-144.99%-16.05%20.56%-11.63%34.64%48.54%-43%-31.16%-15.99%-378%
Net Income-207.9M-227M-172.01M-159.56M-97.81M-96.27M-72.73M-113.92M-146.95M-167.81M
Depreciation & Amortization4.12M3.87M2.6M10.46M8.38M13.16M-14M-925K3.19M5.65M
Stock-Based Compensation43.33M35.41M17.24M-1.13M3.12M5.03M6.02M4.62M5.39M9.45M
Deferred Taxes323.75K403.22K00184K00000
Other Non-Cash Items182.99K1.03M381K220K656K66K99K-3K15.84M102.5M
Working Capital Changes-968.44K-445.6K3.45M-15.6M-22.77M22.32M953K5.75M1.34M1.36M
Change in Receivables4.22K1.68M34K-2.07M2.15M00000
Change in Inventory-5M-2.14M-527K2.33M-16.18M000-16.11M-8.77M
Change in Payables4.69M12.43M-7.65M-5.08M-7.56M3.46M8.42M272K15.83M4.83M
Cash from Investing-11.03M-11.81M-5.66M-2.87M-433K-100K-808K-757K-1.37M-1.3M
Capital Expenditures-10.62M-6.49M-5.57M-2.79M-918K-754K-677K-2.34M0-149K
CapEx % of Revenue92.2%50.67%37.85%24.73%16.08%15.71%4.3%---
Acquisitions0000511.01K7.61K0000
Investments----------
Other Investing00-30K26K604K-61101.58M-1.37M-1.15M
Cash from Financing402.58K178.62M207.58M149.55M274K194.1M6.77M587K276.18M365.97M
Debt Issued (Net)-578K-1.8M-4.65M-303K-582.92K-474K0000
Equity Issued (Net)1M151.7M208.94M149.89M978K194.59M6.77M587K277.04M276.51M
Dividends Paid0000000000
Share Repurchases-29.33K-572.36K0-563K00-154K-47K00
Other Financing-163.03K-506.34K3.29M-35K-121.08K-20K00-854.56K89.46M
Net Change in Cash
-166.93M▲ 0%
-20.65M▲ 87.6%
52.68M▲ 355.1%
3.1M▼ 94.1%
-119.05M▼ 3944.1%
131.9M▲ 210.8%
-67.83M▼ 151.4%
-108.91M▼ 60.6%
161.71M▲ 248.5%
216.21M▲ 0%
Free Cash Flow
-171.53M▲ 0%
-193.23M▼ 12.7%
-153.94M▲ 20.3%
-168.42M▼ 9.4%
-109.16M▲ 35.2%
-56.45M▲ 48.3%
-80.33M▼ 42.3%
-106.81M▼ 33.0%
-121.18M▼ 13.4%
-151.2M▲ 0%
FCF Margin %-1489.12%-1507.87%-1046.67%-1493.65%-1912.4%-1176.13%-510.75%---
FCF Growth %-129.52%-12.65%20.33%-9.41%35.19%48.28%-42.29%-32.97%-13.45%-67.15%
FCF per Share-34.64-33.40-20.80-15.57-9.91-3.65-4.22-5.55-21.71-21.71
FCF Conversion (FCF/Net Income)0.91x0.98x0.86x1.04x1.11x0.58x1.10x0.92x0.82x0.90x
Interest Paid0000000000
Taxes Paid0000000000

DBVT Key Ratios

DBV Technologies S.A. (DBVT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)-78.62%-109.14%-95.84%-80.04%-64.24%-65.63%-43.47%-135.72%-150.29%-130.15%
Return on Invested Capital (ROIC)--4441.01%-847.19%-461.04%-259.52%-664.89%-1067.09%-2231.7%-1366.34%
Gross Margin100%100%100%100%-62.46%-322.9%100%---
Net Margin-1538.29%-1484.65%-1169.51%-1415%-1713.54%-2006.25%-462.4%---
Debt / Equity0.04x0.03x0.14x0.08x0.11x0.02x0.05x0.28x0.13x0.13x
Interest Coverage-43.46x-396.92x-452.53x-186.87x-144.25x-227.12x----189.82x
FCF Conversion0.91x0.98x0.86x1.04x1.11x0.58x1.10x0.92x0.82x0.90x
Revenue Growth45.31%11.25%14.77%-23.33%-49.38%-15.91%227.67%-100%--100%

DBVT SEC Filings & Documents

DBV Technologies S.A. (DBVT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 30, 2026·SEC

Material company update

Mar 26, 2026·SEC

Material company update

Mar 2, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 26, 2026·SEC

FY 2024

Mar 7, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 30, 2026·SEC

FY 2025

Oct 28, 2025·SEC

FY 2025

Jul 29, 2025·SEC

DBVT Frequently Asked Questions

DBV Technologies S.A. (DBVT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

DBV Technologies S.A. (DBVT) grew revenue by 0.0% over the past year. Growth has been modest.

DBV Technologies S.A. (DBVT) reported a net loss of $167.8M for fiscal year 2025.

Dividend & Returns

DBV Technologies S.A. (DBVT) has a return on equity (ROE) of -150.3%. Negative ROE indicates the company is unprofitable.

DBV Technologies S.A. (DBVT) had negative free cash flow of $151.2M in fiscal year 2025, likely due to heavy capital investments.

Explore More DBVT

DBV Technologies S.A. (DBVT) financial analysis — history, returns, DCA and operating performance tools

Full DBVT Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.